Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Sources Sought opportunity from Department Of Defense was posted on August 24, 2022. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

cGMP MANUFACTURING FOR VIALS OF ALFQ

Closed
RFI-W81XWH-MT-6006Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

General Info

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Frederick, MD, 21704, USA

Set-Aside

NONE

Documents

1

RFI-W81XWH-22-MT-6006-cGMP+ALFQ-v1.0.docx

DOCX

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseClosed
Posted

Sources Sought

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → W4PZ USA Medical Rsch Acquis Act
Contacts1 person available
OfficeFORT DETRICK, MD, 21702-5014, USA
Office AddressFORT DETRICK, MD, 21702-5014, USA
Contacts

Full Description

Show more
RFI TITLE: CURRENT GOOD MANUFACTURING PROCESS (CGMP) MANUFACTURING FOR VIALS OF THE ARMY LIPOSOME FORMULATION-QS21 (ALFQ) SUBJECT: The USAMMDA is conducting market research to determine whether a commercial solution can be provided to meet requirements for cGMP manufacturing of a minimum of 20,000 vials/lot of vials of the Army Liposome Formulation-QS21 (ALFQ) for Phase 2/3 clinical trials and the capability to manufacture for a commercially licensed vaccine. This market research may also assist with the further development and/or refinement of the requirements. DISCLAIMER: This is an RFI as defined in FAR 15.201(e) to ascertain whether a commercial item exists that provides the capabilities described herein. This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. In keeping with the standards of FAR Part 10, the Government may request additional information from respondents. Respondents are solely responsible for all expenses associated with responding to this RFI or any follow-up information request. All information received in response to this RFI or any follow-up information request that is marked Proprietary will be handled accordingly. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for a future request for proposal will not be entertained. Please reference the attached RFI for details.

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS